DJIA 17,812.19 19.51 0.11%
NASDAQ 5,102.81 0.33 0.01%
S&P 500 2,089.14 2.55 0.12%
market minute promo

Regeneron Pharmaceuticals (NASDAQ: REGN)

567.47 -3.38 (-0.59%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

REGN $567.47 -0.59%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $567.05
Previous Close $570.85
Daily Range $560.53 - $569.93
52-Week Range $383.87 - $605.93
Market Cap $59.1B
P/E Ratio 112.82
Dividend (Yield) $0.00 (0.0%)
Volume 674,095
Average Daily Volume 789,412
Current FY EPS $9.80




Drug Makers

Regeneron Pharmaceuticals (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website:

News & Commentary

3 Stocks to Buy and Hold for the Next Decade

Our contributors highlight three remarkably strong companies to hold for the long term.

Regeneron, Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent Injection Fully Enrolle

Regeneron, Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent Injection Fully Enrolled

Weekly CFO Sells Highlights: Facebook, Fitbit, Regeneron Pharmaceuticals

5 Things Amgen, Inc. Wants You to Know

Amgen may have crushed Wall Street's Q3 forecast, but if you didn't listen to its quarterly conference call, then you probably missed out on these key points concerning its long-term outlook.

Sanofi and Regeneron Hit Another Bullseye

This drug's performance in a difficult-to-treat population gives many rheumatoid arthritis patients something to cheer about.

Favorite Biotech Picks - Cramer's Lightning Round (11/17/15)

'Mad Money' Lightning Round: Procter & Gamble Is Done Going Down

5 Biotechs That Can Win From Ophthalmology Innovation

Vanguard Raises Stakes in Biogen, Mylan, Merck

These 2 Companies Could Revolutionize Heart Disease Prevention

Early human clinical trial results suggest that a better drug for lowering bad cholesterol may be on the horizon.

See More REGN News...

REGN's Top Competitors

REGN $567.47 (-0.59%)
Current stock: REGN
AMGN $162.78 (0.19%)
Current stock: AMGN
GILD $106.57 (0.20%)
Current stock: GILD
BIIB $289.15 (-1.73%)
Current stock: BIIB